A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Levonorgestrel

Cmax of Ethinyl Estradiol and Levonorgestrel.

Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2

Time to Cmax (Tmax) of Ethinyl Estradiol and Levonorgestrel

Tmax of Ethinyl Estradiol and Levonorgestrel.

Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2

Terminal Phase Elimination Rate Constant (β) of Ethinyl Estradiol and Levonorgestrel

β of Ethinyl Estradiol and Levonorgestrel.

Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2

Terminal Phase Elimination Half-Life (t1/2) of Ethinyl Estradiol and Levonorgestrel

t1/2 of Ethinyl Estradiol and Levonorgestrel.

Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2

Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of Ethinyl Estradiol and Levonorgestrel

AUCt of Ethinyl Estradiol and Levonorgestrel.

Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2

Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of Ethinyl Estradiol and Levonorgestrel

AUCinf of Ethinyl Estradiol and Levonorgestrel.

Time frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2

Number of Participants with Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.